These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 16828940)
1. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940 [TBL] [Abstract][Full Text] [Related]
2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
3. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603 [TBL] [Abstract][Full Text] [Related]
4. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312 [TBL] [Abstract][Full Text] [Related]
6. A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258 [TBL] [Abstract][Full Text] [Related]
7. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002 [TBL] [Abstract][Full Text] [Related]
8. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596 [TBL] [Abstract][Full Text] [Related]
9. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663 [TBL] [Abstract][Full Text] [Related]
10. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G; Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042 [TBL] [Abstract][Full Text] [Related]
18. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. Park JS; Oh YK; Kang MJ; Kim CK J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729 [TBL] [Abstract][Full Text] [Related]
19. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781 [TBL] [Abstract][Full Text] [Related]
20. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]